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An intermediate trait of atherosclerosis that is highly predictive for cardiovascular events in humans is carotid intima-media thickening (IMT). 6 -10 Inbred mouse strains that exhibit phenotypic variations are commonly used to discover genetic differences underlying cardiovascular diseases. To study genes that influence IMT we developed a carotid IMT model in mice in which intima is induced by low blood flow. 11 We previously demonstrated by using this model that there are strain-dependent differences in intima thickening that vary significantly among inbred mice. 12 C3HeB/FeJ (C3H/F) mice were resistant to intima formation, whereas SJL/J (SJL) mice exhibited a significant increase in intima thickening. 12 We also reported that SJL mice have increased cell proliferation and endothelial dysfunction, as well, that contribute to intima formation. 13, 14 We mapped 3 quantitative trait loci for intima formation that we termed Intima modifier (Im) loci: Im1 on chr2, Im2 on chr11, and Im3 on chr18. 15 These findings indicate that the intima trait is genetically determined.
Understanding the genetic contribution to cardiovascular disease can be done by transcriptomic analyses of vascular tissues in inbred mice. Such approaches have been important in demonstrating gene expression differences that explain C57BL/6J mouse susceptibility to atherosclerosis in comparison with C3H/HeJ mice. 16 Lutgens et al 17 demonstrated with gene profiling that atherogenesis was highly correlated with increased expression of small inducible cytokines including monocyte chemoattractant protein-1 between C3H/HeJ and C57BL/6J. This finding was later strengthened by microarray and bioinformatic pathway analyses that found that alterations in calcium signaling contributed to the differences in monocyte chemoattractant protein-1 production in these strains. 18 To identify candidate genes that might localize to our previously published Im1, Im2, and Im3 loci, 15 we used a similar combinatorial approach of microarray and bioinformatic pathway analyses in C3H/F and SJL inbred mice. We confirmed some known pathways such as antigen presentation and processing in the immune pathway and discovered a new one, the ribosome pathway. We further validated and proposed a functional role for 1 specific gene in the ribosome pathway, ribosomal protein L17 (RpL17). Our data provide evidence that RpL17 is a vascular smooth muscle cell (VSMC) growth inhibitor, akin to a tumor suppressor. This finding is significant, because it is the first to show that a ribosomal protein functions to inhibit VSMC cell cycle progression and growth, making it a potential therapeutic target to limit carotid IMT.
Materials and Methods
Methods are expanded in the online-only Data Supplement.
Animals and Surgeries
Sham operations and ligations on male mice from each strain (C3H/F and SJL) were performed as described. 11 Four groups of mice were examined: C3H/F shams (nϭ4), C3H/F ligated (nϭ5), SJL shams (nϭ4), and SJL ligated (nϭ5).
Microarray and Kyoto Encyclopedia of Genes and Genomes Analysis of Carotid Arteries
Carotids were harvested at day 14 after surgery and immediately frozen in liquid nitrogen for total RNA isolation with the use of the Qiagen RNAeasy Micro kit. RNA was processed to amplified cDNA by using NuGen's Ovation RNA Amplification System V2 with final purification of the amplified cDNA done with the use of the NucleoSpin Extract I kit. Fragmentation and biotinylation of the amplified cDNA was accomplished by using NuGen's FL-Ovation cDNA Biotin Module V2 and hybridized to Affymetrix GeneChip M430 2.0 arrays. Washing, staining, and scanning of these arrays was done by using the Affymetrix FS-450 Fluidics station and the Affymetrix GeneChip Scanner 3000. Each array contained gene expression level information of 45 037 probe sets of the 39 000 known transcripts for 34 000 known or predicted mouse genes. The probe level data were assembled to a unique number representing the expression level by using the robust multiarray analysis preprocessing procedure, which is available in the BioConductor package 19 for R software. 20 We conducted the following sample comparisons to identify differentially expressed genes: (1) C3H/F shams versus SJL shams, (2) C3H/F shams versus C3H/F ligated, (3) SJL shams versus SJL ligated, and (4) C3H/F ligated versus SJL ligated. For each comparison, we used the Delta-sequence method to select differentially expressed genes. The Delta-sequence method exploits a special structure in gene expression data that produces a sequence of weakly dependent random variables. This method has 2 distinct advantages. First, it leads to dramatic gains in terms of testing power, and in the stability of the results of testing, as well. Second, its outcomes are entirely free from the log-additive array-specific technical noise, so no normalization is needed. Therefore, in the current study, we used the Delta-sequence method (with the shift method) in conjunction with the 2-sample Student t statistics. Then, as in the global normalization method, we applied the Bonferroni multiple testing procedure to select differentially expressed genes at a per-family error rate level 10. 21 We compared gene sets by using the Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analyses. 22 With the use of BioConductor package Category, 19 we mapped all KEGG pathways to genes in the Affymetrix M430 2.0 array. For every pathway we tested the hypothesis whether the pathway was differentially expressed between the 2 strains (C3H/F versus SJL) by using N-statistics. 23 The complement of correlation coefficient between gene expression vectors was used as a distance measure. We then aimed to map differentially expressed genes to the intima quantitative trait loci 24 in KEGG pathways. To visualize gene expression in the ribosome pathway we constructed heat maps representing hierarchical clustering of ribosomal protein gene expression vectors. The complement of correlation coefficient between gene expression vectors was used as a distance measure.
Pluronic Gel Delivery of siRNA in Vivo
C3H/F male mice were anesthetized as described. 11 Pluronic gel (BASF F127, Prill) was made as a 4% solution (2 g dissolved in 5 mL of ice-cold sterile phosphate-buffered solution) and kept on ice. Application of pluronic gel was done similarly as described. 25 Carotid arteries were isolated by gently dissecting the common carotids free of connective tissue. A 6.0 silk suture was placed beneath the common carotid and gently used to lift the carotid out of the neck cavity. Twenty-five microliters of ice-cold pluronic gel containing either scrambled small interfering (siRNA) (siScr) (100 nmol/L) or RpL17 siRNA (siRpL17) (100 nmol/L) (Santa Cruz Biotechnology) was applied to the neck cavity, the suture was removed to release the carotid back into the neck, and another 25 L of pluronic gel containing siRNA was applied to the top of the carotid. siRpL17 was applied to the left carotid and siScr to the contralateral right carotid, as an internal control. The incision was sutured, and mice were individually housed and allowed to recover. Carotid arteries were harvested at days 0, 1, 3, and 7 following siRNA delivery. RpL17 knockdown was greatest at day 3. At day 7 following siRNA delivery, RpL17 levels returned to those observed at day 0.
Carotid Ligation and Immunohistochemistry
Ligations of carotid arteries in male mice from C3H/F and SJL were performed as described. 11 Carotid arteries were harvested 7 days after surgery. Mice were perfused and fixed in 4% paraformaldehyde and vessels paraffin embedded. Sections were deparaffinized and rehydrated in Tris-buffered solution. Slides were incubated in 3% H 2 O 2 and washed with Tris-buffered solution. Antigen retrieval was done by using heat-induced epitope retrieval 10 mmol/L citrate buffer (pH 6.0) followed by washing in Tris-buffered solution. Sections were blocked with 5% normal horse serum (DakoCytomation) for 30 minutes followed by primary RpL17 antibody (Everest Biotech Ltd; 1:1000 in Dako antibody dilutent) for 60 minutes. Normal goat IgG (Santa Cruz Biotechnology) was used as a negative control (1:1000). For RpL17, sections were washed with Trisbuffered solution and incubated in secondary biotinylated horse anti-goat IgG antibody with the Vectastain ABC kit (PK-6100, Vector Laboratories, Inc) (1:500) for 30 minutes. For proliferating cell nuclear antigen (PCNA) sections were blocked in Dako antibody dilutent followed by PCNA (Thermo Scientific) (1:500) overnight at 4°C. Protein was detected by using Liquid DABϩsubstrate Chromogen system (DakoCytomation) and counterstained with hematoxylin. Slides were imaged by using an Olympus BX41 microscope with digital camera at 60ϫ (Spot Insight 2, Diagnostic Instruments). Quantification was done by using ImagePro Plus software as described previously. 26 For each image, a pixel threshold was set for nuclei in the medial and intimal area. This allowed the software to provide a total cell number count. A second measurement for the same area was acquired by using an adjusted pixel threshold for cells staining positively for RpL17 and PCNA.
Statistical Analyses
Microarray statistical analysis is described in detail above. In all other experiments where data sets from Ͼ2 groups were being
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compared, a 1-way analysis of variance was used. In cases where only 2 groups were being compared, a Student t test was used.
Results

Microarray and KEGG Analyses Between Carotids From Mouse Strains
We performed a microarray of 34 000 genes and found 276 differentially expressed transcripts in the carotids of C3H/F mice in comparison with SJL mice. (online-only Data Supplement Tables II to VIII show the complete list of genes that differed between groups). We arranged the complete list of 276 genes from our microarray analyses into pathways by using KEGG to look for significant differences in pathways. We used KEGG because it has the ability to reduce the number of testable pathways and gene candidates between mouse strains. With the use of the KEGG database, we found 4 categories (including 15 pathways) that were differentially expressed between C3H/F and SJL carotids (Table) . The 4 categories were metabolism, genetic information and processing, cellular process, and human disease. Accordingly, the KEGG analysis confirmed our previously reported difference in the immune pathway 13 (subcategory of cellular process in the Table) and also identified novel pathways that included differentially expressed genes from the microarray analysis. Several genes identified in the microarray fell into KEGG pathways that likely contribute to the intima trait (online-only Data Supplement Table IX ). These include Casp9 (involved in apoptosis and fits our previous observations of dramatic differences in apoptosis between remodeled C3H/F and SJL carotid arteries 13 ), Dclre1c (Artemis) (immunodeficiency pathway), CD47 (receptor in extracellular matrix-receptor interactions), Frz4 (involved in the WNT-signaling pathway), Smurf2 (transforming growth factor signaling), IRF3 (tolllike receptor signaling), Nln (renin-angiotensin system), Serpin1b (complement and coagulation cascades), PRP19 (ubiquitin-mediated pathways), and our prime candidate, RpL17 (component of the large 60S ribosome). Among these genes, RpL17 was the only one that was significantly different in between-strain comparison and in sham and ligated comparisons, as well (online-only Data Supplement Tables I  and VIII) . We also performed cluster analysis of ribosomal proteins and found that RpL17 expression was higher in all C3H/F mice in comparison with SJL (online-only Data Supplement Figure I ). Thus, we identified important genes and pathways whose expression differed significantly in carotid arteries between C3H/F and SJL mice.
Validation of Differences in RpL17 Expression
We chose to further validate RpL17 because of its significant difference in gene expression from the microarray, representation in KEGG pathways analysis (online-only Data Supplement Table IV ) and heat map analysis (online-only Data Supplement Figure I ) and location relative to the Im3 locus on chr18. We performed quantitative reverse transcription polymerase chain reaction for RpL17 expression in C3H/F and SJL carotid arteries. There was a significant increase in RpL17 expression in C3H/F in both shams (50-fold) and after ligation (41-fold) in comparison with SJL ( Figure 1A ). We used cultured mouse aortic smooth muscle cells (MASMCs) from C3H/F and SJL aortas to establish a model to analyze the functional consequences of differences in RpL17 expression. We focused on cell growth because we previously showed that, in response to low flow, C3H/F carotids exhibit dramatically less proliferation in comparison with SJL. 13 We found that C3H/F MASMCs grew significantly slower than SJL MASMCs ( Figure 1B) , consistent with the in vivo cell proliferation data. 13 Importantly, quantitative reverse transcription polymerase chain reaction demonstrated that RpL17 expression in MASMCs was Ͼ6-fold higher in C3H/F than in SJL at passage 4 ( Figure 1C ). We also measured RpL17 protein expression in MASMCs. The representative immunoblot ( Figure 1D ) shows the magnitude of increase (Ϸ2.5-fold) in RpL17 expression in C3H/F in comparison with SJL MASMCs. Similarly, we found that RpL17 protein expression was greater in C3H/F aortas than in SJL aortas (online-only Data Supplement Figure II ).
Cell Cycle Analysis Reveals Increased S Phase in SJL MASMCs
Our in vitro MASMC model confirmed that VSMCs from C3H/F grow slower in comparison with SJL ( Figure 1B) . By propidium iodide staining and flow cytometry, we characterized cell cycle as shown in Figure 2 . MASMCs from C3H/F were primarily arrested in G 0 /G 1 phase, whereas SJL exhibited a dramatic increase in percentage of cells in S phase (Figure 2A through 2C ; online-only Data Supplement Table  X) . A specific comparison at basal (0 hours) and after 24 hours of serum stimulation revealed a significant increase in the percentage of cells in S phase relative to G 0 /G 1 in SJL MASMCs in comparison with C3H/F. To confirm these cell cycle differences, we used cyclin D1, a cell cycle-dependent kinase often measured as an index of cell cycle progression. 27 There was a dramatic difference in cyclin D1 expression, with higher levels in SJL MASMCs than in C3H/F, especially at 24 hours ( Figure 2D ). These data strongly support our previous findings that SJL VSMCs are highly proliferative in comparison with C3H/F.
RpL17 Depletion in Vitro Increases VSMC Proliferation
To determine whether changes in RpL17 expression altered cell cycle, we depleted RpL17 in VSMCs. siRNA-mediated knockdown of RpL17 significantly decreased its expression in rat aortic vascular smooth muscle cells (RASMCs) ( Figure  3A ). After 24 hours of serum stimulation, RASMCs deficient in RpL17 had a significant increase in the ratio of cells in S phase relative to G 0 /G 1 , similar to the cell cycle data for SJL ( Figure 3B and 3C; online-only Data Supplement Table XI ). We also found that decreasing RpL17 mRNA in human aortic VSMCs resulted in an increase in cells in S phase in comparison with G 0 /G 1 (online-only Data Supplement Figure  III ; online-only Data Supplement Table XII ). Thus, we used 3 different in vitro VSMC lines, mouse, rat, and human, and demonstrated that RpL17 regulates VSMC cell cycle, especially progression to S phase. Previously we showed that after carotid ligation C3H/F intima exhibited more apoptotic cells in comparison with SJL. 13 Ribosomal proteins have been shown to be mediators of apoptosis. For example, overexpression of RpL7 in T-lymphoma cells 28 and RpS3a in tumor cells 29 can induce apoptosis. Therefore, we investigated if RpL17 expression affected apoptosis. With the use of flow cytometric analysis with Annexin V and propidium iodide staining, we found no effect on apoptosis or necrosis when RpL17 expression was decreased by siRpL17 ( Figure 4 ; online-only Data Supplement Figure IV) . These findings suggest that RpL17's predominant role is to regulate VSMC growth and not apoptosis. 
RpL17 Depletion in Vivo Increases VSMC Proliferation
To determine whether changes in RpL17 expression are sufficient to alter cell proliferation in vivo, we decreased RpL17 expression by using pluronic gel delivery of siRpL17 in C3H/F left carotid arteries ( Figure 5 ). As an internal control siScr was applied to the contralateral right carotid arteries of all animals. After 3 days of siRNA delivery, we harvested carotids and immunostained for RpL17 and PCNA in serial sections. In the control (siScr) right carotids there was no effect on RpL17 expression ( Figure 5A and 5B, insets) or PCNA expression ( Figure 5C and 5D, insets). However, with siRpL17 in the left carotids, we showed an Ϸ2.5-fold decrease in cells expressing RpL17 ( Figure 5A and 5B, quantified in 5E) that correlated with an Ϸ8-fold increase in PCNA expression ( Figure 5C and 5D ; quantified in 5F). These data show that decreasing RpL17 expression in the carotid artery increases proliferation of medial VSMCs. This finding is highly significant, because it indicates that RpL17 is a VSMC growth inhibitor in vivo (akin to a tumor suppressor).
Intimal Proliferating Cells Have Decreased RpL17 Expression
We demonstrated that depletion of RpL17 increased VSMC proliferation in vivo ( Figure 5) . We have previously shown that SJL carotids have an increased number of proliferating cells in the intima in comparison with C3H/F in response to low blood flow. 13 To determine whether this increase in the number of proliferating cells was a result of a decreased number of RpL17-expressing cells, we immunostained carotids from C3H/F and SJL 7 days following partial carotid ligation ( Figure 6 ). Immunohistochemistry showed greater RpL17 protein expression in C3H/F ( Figure 6A ) than in SJL ( Figure 6B ). PCNA staining in serial sections indicated that SJL cells ( Figure 6D ) were more proliferative in comparison with C3H/F ( Figure 6C ). RpL17-and PNCA-expressing cells were quantified relative to the total number of cells in the intima and media ( Figure 6E and 6F ). We found that there is an inverse relationship between RpL17 expression and cell proliferation. In particular, in SJL, the number of RpL17expressing cells was decreased and the number of PCNAexpressing cells was increased after 1 week of injury. Thus, our in vivo data support a role for RpL17 in the regulation of intima and media cell proliferation.
Discussion
The major finding of this study is the identification of RpL17 as a novel vascular smooth cell growth inhibitor. Specifically, we showed that (1) the ribosome pathway is a key mediator of carotid intima formation in response to injury, (2) RpL17 can maintain VSMCs in G 0 /G 1 and inhibit growth in 3 in vitro cell lines, (3) decreasing levels of RpL17 expression specifically with siRNA in vivo caused cell proliferation, and (4) following injury, the intima and media of SJL carotids have decreased RpL17-expressing cells and an increased number of proliferating cells. Our data provide strong evidence for a functional role of RpL17 in VSMC-mediated intima formation. This study is important because it is the first to show that a ribosomal protein can function to prevent VSMC cell cycle progression, similar to tumor suppressor genes, while having no effect on cell apoptosis. Thus, a ribosomal protein, RpL17, is a novel VSMC growth regulator that warrants further investigation in vascular biology.
Carotid IMT is a complex multigenetic trait that is highly predictive for cardiovascular events. We used a microarray and bioinformatic approach to identify candidate genes for IMT. Such approaches have been useful in identifying causal genes for complex cardiovascular diseases. For example, by using microarray with likelihood-based causality model selection and comparative human genome-wide association studies it was reported that C3ar1 is a causal gene for aortic lesion development in an atherosclerotic mouse model. 30 Another recent study used tagged single-nucleotide polymorphism mapping in combination with microarray and gene pathway analyses of cultured VSMCs to identify Id3 as having a functional role in regulating IMT. 31 In our study, we used KEGG to narrow our microarray gene list. We identified a number of genes that are involved in pathways already likely to play a role in intima formation and 1 novel candidate. Three of the identified genes localized to our quantitative trait loci for strain-dependent intima formation 15 : Dclre1c (Im1), Serpin1b (Im2), and RpL17 (Im3). Given the already known roles for Dclre1c and Serpin1b, we chose to focus on RpL17. Interestingly, RpL17 was the only gene whose expression differed significantly between strains in both sham and ligated carotids. This makes RpL17 a strong novel candidate. We present functional data that implicate RpL17 as having a significant role in influencing the intima trait via regulation of VSMC growth. We observed that MASMCs from C3H/F grew significantly slower in comparison with SJL. This is consistent with a previous finding that showed that VSMCs from another C3H substrain, C3H/HeJ, grew more slowly than cells iso-lated from FVB/NJ mice. 32 Like SJL, FVB/NJ mice exhibit greater intima formation in response to low blood flow. 12, 32 The decreased growth rate in C3H/F MASMCs appears to be related to changes in cell cycle, because C3H/F cells arrested E PCNA Fold Change in G 0 /G 1 had higher levels of RpL17 than SJL MASMCs. This conclusion is supported by a previous study demonstrating that overexpression of RpL7 in T lymphocytes promoted G 0 /G 1 arrest. 28 In contrast to C3H/F, SJL MASMCs are more proliferative as evidenced by the high ratio of cells in S phase in comparison with G 0 /G 1 . Importantly, we also found that depletion of RpL17 in both rat and human VSMCs phenocopied the SJL cell cycle distribution, strongly supporting a role for RpL17 as a key contributing regulatory factor for VSMC cell cycle progression. Consistent with the in vitro RpL17 depletion results, we found that decreasing RpL17 expression in C3H/F carotids resulted in increased cell proliferation. Furthermore, we found a significant increase in RpL17-expressing cells relative to proliferating cells in the intima of C3H/F mice after injury. Conversely, in SJL, there was a decrease in RpL17-expressing cells and an increase in cell proliferation. These collective data strongly indicate that RpL17 can function like a tumor suppressor. Because we saw no effect on apoptosis in vitro following RpL17 depletion, it is probable that VSMC proliferation is more dependent on RpL17's regulation of cell growth and proliferation and not apoptosis. Thus, we would propose that candidate genes other than RpL17, most likely those present in the Im1 and Im2 loci, are involved in the apoptotic pathways observed in C3H/F carotids. 13 Although RpL17 is part of the translational machinery, it is possible that its inhibitory effect on growth may exist outside of the ribosome (extraribosomal) to alter cellular processes such as cell cycle and gene transcription. [33] [34] [35] Some diseases involving dysfunctions in cell cycle and growth have been directly attributed to deletions or mutations in ribosomal proteins. Mutations in RpS14 are related to 5q-syndrome, 36 and RpS19 and RpS35a deficiencies result in Diamond-Blackfan anemia. 37 Interesting, as in our study, RpS35a was identified in the anemic disorder by using genomic mapping and microarray analysis. 37 Ribosomal proteins are also differentially expressed in colorectal, 38 gastric, 39 nasopharyngeal, 40 and prostate 41 cancers. Specific ribosomal proteins have been to shown to function in an extraribosomal manner as either tumor promoters (RpL19) 41 or tumor suppressors (RpL5, RpL11, and RpL23 [which is the human homolog for RpL17]). 35, 39, 42 RNA interference-mediated knockdown of RpL19 in a prostate cell line (PC-3 M cells) emphasized the importance of RpL19 in inhibiting the transformation of benign cells to malignant ones. 41 Relevant to our findings, studies using an osteosarcoma cell line demonstrated that RpL5 and RpL11 cooperatively act to increase G 1 arrest. [42] [43] [44] [45] [46] Tumors that are deficient in one or both of these ribosomal proteins have increased cell growth. 46, 47 Our results strongly suggest that RpL17 may serve an extraribosomal function as a tumor suppressor gene in VSMC, opening novel avenues of mechanistic investigation into the regulation of VSMC growth by RpL17, which could be applicable to not only carotid intima thickening, but possibly also to angiogenesis.
Because intima is a complex trait, we acknowledge that other pathways and candidate genes should be considered in future studies. The KEGG analysis identified significant differences in the antigen-processing and presentation pathways, confirming our previous findings that the inflammatory response contributes significantly to intima thickening. 13, 26, 48 We previously demonstrated that cytokines interleukin-18 and migration inhibitory factor were differentially expressed between C3H/F and SJL carotids 13 and that SJL mice have endothelial dysfunction. 14 A recent study showed that a ribosomal protein, RpS19, colocalized and interacted with migration inhibitory factor, resulting in a decreased inflammatory response in aortic endothelial cells. 49 Thus, there could be a potential for interplay between pathways such that ribosomal proteins may play a role in regulating inflammation and vascular wall responses associated with intima formation.
We acknowledge there are limitations to our study. Although we demonstrated that local knockdown of RpL17 in the carotid artery under basal conditions results in an increase in the number of proliferating cells, it would be interesting to see what effect RpL17 knockdown has on intima formation following carotid ligation. However, we observed that, at 7 days after ectopic delivery of siRpL17, the number of RpL17 expressing cells returned to levels observed at day 0 (data not shown), indicating a potential time-dependent effect. Thus, there are technical difficulties in long-term siRNA-mediated knockdown. Additionally, because intima formation is a polygenic trait, it is likely that there will also be contributions from the Im1 and Im2 loci. In our future studies, we are creating congenic mice for our 3 previously published quantitative trait loci (Im1, Im2, and Im3) by using Ϸ4000 SNPs that differ between SJL and C3H/F mice. RpL17 resides on chr18 near the Im3 locus. Introgressing chr18 segments from the SJL mouse on the C3H/F background will provide the ability to directly investigate the effects of RpL17 on intima formation, and the percentage of contribution attributable to the locus and the gene, as well.
In summary, we identified a role for RpL17 as a novel inhibitor of VSMC growth (akin to a tumor suppressor), providing a potential therapeutic target for carotid IMT with potential applicability to angiogenesis in humans.
